I have looked at LL’s HIV trials, and maybe Ohm

Quote:

---

I have looked at LL’s HIV trials, and maybe Ohm can comment, but I don’t think there have been any mutations that appear with LL- not certain.

---

In regular HIV drugs mutations occur to escape the particular target of the drug. Leronlimab doesn't target a specific part of the virus but the binding and replication itself. With leronlimab the only viable mutation is a switch to the CXCR4 receptor.

Leronlimab use results in an extremely low replication rate with a large part of the viral load that does exist coming from viral reservoirs. With low replication you have much less of a chance for mutations to occur. In the trials there were one or two patients that had CXCR4 HIV but it existed before the patient started the trial and it was missed due to extremely low levels of that variant.